Retatrutide and appetite suppression: what TikTok skips

What did @wonderwomanbeauty actually say?

Honestly, not much, at least not explicitly. The transcript is mostly theatrical: "I am literally so freaking hungry. I could eat all of this." The video's meaning lives in its hashtags, not its words. The tags #retatrutidetransformation and #retatrutideeffect do the heavy lifting, implying the creator is on retatrutide and that the hunger they're describing is somehow notable, dramatic, or unexpected given that context.

Whether they're claiming the hunger is a side effect, a break from expected appetite suppression, or just general content filler is genuinely unclear. That ambiguity matters, because viewers filling in the blanks may walk away with assumptions the creator never technically made. The 52,000+ views mean those assumptions are spreading, which is exactly why it's worth unpacking.

Does the science back this up?

Retatrutide is a triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously, and in clinical trials it has produced some of the most dramatic weight loss numbers in the field so far. But appetite suppression is not constant or universal.

The Phase 2 trial published by Jastreboff et al. (2023, New England Journal of Medicine) showed participants on retatrutide lost up to 24.2% of body weight over 48 weeks, significantly outperforming semaglutide comparisons. However, the same trial documented nausea, vomiting, and variable appetite responses, particularly during dose escalation periods. Appetite suppression is dose-dependent and can fluctuate. Some patients report breakthrough hunger, especially early in a titration phase or after a missed dose. So the framing of "I'm so hungry" while on a triple agonist is not biologically impossible. It's just poorly explained here.

What did they get wrong (or right)?

Let's be fair: the creator didn't technically make a false claim. They expressed hunger. That's it. But context-by-hashtag is still a form of claim-making, and that framing has problems.

First, presenting dramatic hunger as a novelty while using retatrutide hashtags could mislead viewers into thinking this is a rare or alarming side effect, when variable appetite is a documented and expected part of the titration process. Second, normalizing self-injection peptide use on a platform with a median user age under 30 carries real risk. Retatrutide is not FDA-approved. It is available only through compounding pharmacies under prescriber supervision, and the quality control landscape for compounded peptides is not uniformly regulated.

What they got right, inadvertently: real GLP-1 receptor agonist users do experience hunger variation. It is not a magic off switch. That's an honest, if unintentional, counter-narrative to the "never hungry again" marketing that floods this corner of TikTok.

What should you actually know?

Retatrutide is not FDA-approved as of 2024. It is in Phase 3 trials and available through compounding pharmacies only with a valid prescription. That distinction matters, because compounded formulations are not equivalent to FDA-reviewed products, full stop.

The hunger fluctuation shown in this video, while vague, reflects a real pharmacological reality. GLP-1 receptor agonists including retatrutide work partly by slowing gastric emptying and modulating hypothalamic hunger signals, but those effects vary based on dose, timing, individual metabolic response, and adherence. A study by Müller et al. (2022, Nature Reviews Drug Discovery) notes that triple agonists show more complex appetite modulation than single-pathway drugs, meaning the experience is genuinely less predictable.

If you're considering any GLP-1 class peptide, that conversation belongs with a licensed prescriber reviewing your full metabolic picture, not a TikTok comment section.